Home/General Biologicals Corporation/Mr. Kevin Wang

MK

Mr. Kevin Wang

CFO

General Biologicals Corporation

Therapeutic Areas

Oncology Immunology Infectious Diseases

General Biologicals Corporation Pipeline

Drug	Indication	Phase
GBC-001	B‑cell malignancies (CD19+)	Phase 1
GBC-002	HER2‑positive solid tumors	Pre‑clinical
GBC-003	Influenza and emerging viral infections (mRNA vaccine)	Phase 1/2

Leadership Team at General Biologicals Corporation

View full General Biologicals Corporation profile